KAKKIS EMIL D 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO
Transactions
- Award
Common Stock
2024-03-01+38,428→ 578,198 total - Tax Payment
Common Stock
2024-03-01$53.69/sh−17,417$935,119→ 560,781 total - Award
Common Stock
2024-03-01+3,132→ 563,913 total - Award
Stock Option (Right to Buy)
2024-03-01+70,094→ 70,094 totalExercise: $53.69Exp: 2034-03-01→ Common Stock (70,094 underlying)
Holdings
- 2,263,985(indirect: See FN)
Common Stock
Footnotes (6)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F3]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.